Tags » Warner Chilcott

Denosumab increased adherence, BMD in postmenopausal patients.

Patients previously treated with a bisphosphonate who still have a high risk for fracture may benefit from the addition of denosumab, according to data presented at ASBMR 2013. 269 more words


US Stock Chart of the Day. Warner Chilcott (WCRX)

Warner Chilcott (WCRX)

Warner Chilcott is a pharmaceutical company which focuses on women’s healthcare, gastroenterology, dermatology and urology segments of the North American. It develops the therapeutic products for the treatment of diseases related to the dermatology, musculoskeletal, women’s healthcare and general healthcare and community. 146 more words


Actavis buys Warner Chilcott

May 22, 2013 | By Márcio Barra

This Monday, It was confirmed that Actavis, the largest U.S. maker of generic drugs by market value, will acquire Ireland based, specialty pharmaceutical company Warner Chilcott in a stock-for-stock $8.5 billion deal, bigger than the previously reported $5 billion. 291 more words


Warner Chilcott to be bought for $8.5 billion

Dundalk-based pharmaceutical giant Warner Chilcott is set to be bought by Actavis in an all-stock transaction valued at about $8.5 billion.

The deal would create the third biggest speciality pharmaceutical company in the US. 69 more words

Local News

Report on Partnering Agreements with Warner Chilcott 2005-2012

The Partnering Agreements with Warner Chilcott report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. 581 more words

Market Research Reports

Screen of the Week 04/24/2012: The Right Way to Find Growth and Value Stocks

By: Kevin Matras
April 24, 2012

Looking for growth and value is a winning combination.

Especially now, with concerns over slowing growth and rich valuations. 933 more words